Dr. Ravi Narra
Dr. Ravi Narra
Oncology
MD, MS, Haematology, Medical Oncology (USA)
Registered Number – 1891009387
Milwaukee
Experience – 12 years
Languages – English, Hindi, Telugu
Detailed Experience
Dr. Ravi Narra, an esteemed Hematology and Medical Oncology specialist with a remarkable 12-year journey dedicated to advancing cancer care. With MD and MS qualifications in Haematology and Medical Oncology from the USA, Dr. Ravi Kishore Narra has established himself as a beacon of expertise in Haematology and Medical Oncology. His proficiency extends to treating a range of conditions, including Acute & Chronic Leukemia, Lung Cancer, Lymphoma, Myelodysplastic Syndromes (MDS), and Plasma Cell Disorders for both adults and senior citizens. Dr. Ravi Narra's mission is to provide a holistic and personalized approach to cancer care, ensuring that each patient receives tailored treatment plans that align with their unique needs. His dedication extends beyond medical interventions; he values open communication, patient education, and emotional support.
Education & Training
Osmania Medical College – Hyderabad – India – Doctor of Medicine – (2007)
Advocate Illinois Masonic Medical Center – Chicago – IL – Residency in Internal Medicine – (2011-2013)
Medical College of Wisconsin – Milwaukee – Masters in Clinical and Translational Science – (2017-2018)
Medical College of Wisconsin Affiliated Hospitals – Milwaukee – Fellowship in Hematology & Oncology – (2018-2021)
Publications (12)
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. (Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR) Clin Genitourin Cancer 2023 Feb;21(1):55-62 PMID: 36411184 SCOPUS ID: 2-s2.0-85142487844 11/22/202
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. (Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N) Hematol Oncol 2022 Feb;40(1):48-56 PMID: 34763367 SCOPUS ID: 2-s2.0-85119403860 11/12/2021
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. (Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N) Hematol Oncol 2022 Feb;40(1):48-56 PMID: 34763367 SCOPUS ID: 2-s2.0-85119403860 11/12/2021
Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. (Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC) J Surg Res 2020 Nov;255:99-105 PMID: 32543385 SCOPUS ID: 2-s2.0-85086399641 06/17/2020
From Theory to Practice: Implementation of Strategies to Reduce Acute Care Visits in Patients With Cancer.(Daly B, Michaelis LC, Sprandio JD, Kapke JT, Narra RK, Malosh E, Zervoudakis A, Holland J, Zablocki M) Am Soc Clin Oncol Educ Book 2020 May;40:85-94 PMID: 32421450 05/19/2020
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D’Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020
Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D’Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2s2.0-85083636589 03/07/2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D’Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.085080146585 01/27/2020
Allogenic transplant for non-hodgkin lymphoma (Narra RK, Shah NN) Hematopoietic Cell Transplantation for Malignant Conditions 1 January 2019:209-229 SCOPUS ID: 2-s2.085082261875 01/01/2019
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D’Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.085059680507 12/21/2018
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D’Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.085059680507 12/21/2018
Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. (Vazirabad I, Chhabra S, Nytes J, Mehra V, Narra RK, Szabo A, Jerkins JH, Dhakal B, Hari P, Anderson MW) Biol Blood Marrow Transplant 2019 May;25(5):921-931 PMID: 30537549 SCOPUS ID: 2-s2.0-85060298203 12/12/2018
Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 Oct;12(5):415423 PMID: 28944397 PMCID: PMC6045428 SCOPUS ID: 2-s2.0-85029897925 09/26/2017
Synchronous Tumors: Adenocarcinoma of the Esophagus and Clear Cell Renal Carcinoma. (Narra RK, Alvarez Argote J, Mesologites T, Dasanu CA) Conn Med 2015 Aug;79(7):401-4 PMID: 26411176 SCOPUS ID: 2-s2.0-84940653430 09/29/2015
